NYSE:NSPR InspireMD (NSPR) Stock Price, News & Analysis $2.65 +0.07 (+2.71%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends About InspireMD Stock (NYSE:NSPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get InspireMD alerts:Sign Up Key Stats Today's Range$2.58▼$2.6850-Day Range$2.28▼$2.7852-Week Range$1.81▼$3.42Volume19,612 shsAverage Volume24,882 shsMarket Capitalization$69.11 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingBuy Company OverviewInspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Read More… 2024 Election Year Stocks: Uncover Hidden Gems! (Ad)In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.Secure your copy now by clicking this link. InspireMD Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks49th Percentile Overall ScoreNSPR MarketRank™: InspireMD scored higher than 49% of companies evaluated by MarketBeat, and ranked 597th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingInspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageInspireMD has only been the subject of 1 research reports in the past 90 days.Read more about InspireMD's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for InspireMD are expected to grow in the coming year, from ($0.79) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InspireMD is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InspireMD is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInspireMD has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about InspireMD's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NSPR. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInspireMD does not currently pay a dividend.Dividend GrowthInspireMD does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for NSPR. News and Social Media1.8 / 5News Sentiment0.30 News SentimentInspireMD has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for InspireMD this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added InspireMD to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InspireMD insiders have not sold or bought any company stock.Percentage Held by Insiders29.72% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about InspireMD's insider trading history. Receive NSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter. Email Address NSPR Stock News HeadlinesInspireMD, Inc. (II2.F)November 21 at 11:55 PM | nz.finance.yahoo.comInspireMD, Inc. (NASDAQ:NSPR) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.November 23, 2024 | Priority Gold (Ad)InspireMD Inc. Reports Q3 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comInspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ...November 13, 2024 | finance.yahoo.comInspireMD Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | markets.businessinsider.comWhat To Expect From InspireMD Inc (NSPR) Q3 2024 EarningsNovember 11, 2024 | finance.yahoo.comInspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 8, 2024 | globenewswire.comSee More Headlines NSPR Stock Analysis - Frequently Asked Questions How have NSPR shares performed this year? InspireMD's stock was trading at $2.81 on January 1st, 2024. Since then, NSPR shares have decreased by 5.7% and is now trading at $2.65. View the best growth stocks for 2024 here. How were InspireMD's earnings last quarter? InspireMD, Inc. (NYSE:NSPR) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. The business earned $1.81 million during the quarter, compared to analysts' expectations of $1.74 million. InspireMD had a negative trailing twelve-month return on equity of 69.42% and a negative net margin of 413.96%. Who are InspireMD's major shareholders? InspireMD's top institutional shareholders include Affiance Financial LLC (0.74%), Parkman Healthcare Partners LLC (0.42%) and Avestar Capital LLC (0.06%). Insiders that own company stock include Gary S Roubin and Paul Stuka. View institutional ownership trends. How do I buy shares of InspireMD? Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of InspireMD own? Based on aggregate information from My MarketBeat watchlists, some other companies that InspireMD investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings11/12/2024Today11/22/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:NSPR CUSIPN/A CIK1433607 Webwww.inspiremd.com Phone9728887766804FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$4.50 Low Stock Price Target$4.50 Potential Upside/Downside+69.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,920,000.00 Net Margins-413.96% Pretax Margin-413.00% Return on Equity-69.42% Return on Assets-57.68% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.05 Sales & Book Value Annual Sales$6.20 million Price / Sales11.15 Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book1.67Miscellaneous Outstanding Shares26,080,000Free Float18,332,000Market Cap$69.11 million OptionableOptionable Beta0.93 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NYSE:NSPR) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InspireMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InspireMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.